SARS-CoV-2 (2019-nCoV) Antigen Reagents

SARS-CoV-2 Spike D614G Mutant

Genomic mutations drive the evolution of all viruses. The mutations enable the virus to escape from immune response and acquire a selective advantage in transmission. A recent study from Los Alamos National Laboratory has identified a major mutation on SARS-CoV-2 Spike initially emerged in European countries. This D614G mutation has rapidly become dominant in these regions, suggesting this mutation may make the SARS-CoV-2 virus more transmissive. It's critical to understand the biology of this variant, particularly in the context of vaccine and drug design.  
 
Sino Biological has developed a recombinant S1 protein with a D614G mutation (40591-V08H3). The recombinant 614G variant demonstrated comparable ACE2 binding as the original 614D, as evidenced in our ELISA analyses. This is consistent with the fact that the mutation is outside of the RBD domain.

In addition to the D614G mutation, several other mutations are also identified. Some of them are believed to enhance S1's ability to bind with ACE2. Sino Biological has developed a panel of mutated RBD proteins to facilitate the study of these variants.

SARS-CoV-2 Antigens

  

SARS-CoV-2 Antibodies

  

SARS-CoV-2 Spike Mutant Protein

S1 SARS-CoV-2 (2019-nCoV) Spike S1 His Protein, D614G
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, V367F
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, K458R
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, F342L
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, V483A
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, A435S
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, N354D
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein, V367F
[ Expressed in HEK293 cell, bind with ACE2]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD His Protein, G476S
[ Expressed in HEK293 cell, bind with ACE2]
   

Biotinylated SARS-CoV-2 Antigen Proteins

N SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Protein, Biotinylated
[ Expressed in Insect cell ]		 N SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Protein, Biotinylated
[ Expressed in HEK293 cell ]
   
S1 SARS-CoV-2 (2019-nCoV) Spike S1-His Protein, Biotinylated
[ Expressed in HEK293 cell, bind with ACE2 ]		 S1 SARS-CoV-2 (2019-nCoV) Spike S1-AVI & His Protein, Biotinylated
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, Biotinylated
[ Expressed in Insect cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, Biotinylated
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-AVI & His Protein, Biotinylated
[ Expressed in Insect cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-AVI & His Protein, Biotinylated
[ Expressed in HEK293 cell, bind with ACE2 ]

Recombinant SARS-CoV-2 Antigens

N SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Protein
[ Expressed in Insect cell ]		 S1+S2 SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Protein
[ Expressed in Insect cell, bind with ACE2 ]
   
S1 SARS-CoV-2 (2019-nCoV) Spike S1-His Protein
[ Expressed in HEK293 cell, bind with ACE2 ]		 S1 SARS-CoV-2 (2019-nCoV) Spike S1-mFc Protein
[ Expressed in HEK293 cell, bind with ACE2 ]
   
S1 SARS-CoV-2 (2019-nCoV) Spike S1-His Protein
[ Expressed in Insect cell, bind with ACE2 ]		 S1 SARS-CoV-2 (2019-nCoV) Spike S1-Fc Protein
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein
[ Expressed in Insect cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-Fc Protein
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein
[ Expressed in HEK293 cell, bind with ACE2 ]
   
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-rFc Protein
[ Expressed in HEK293 cell, bind with ACE2 ]		 RBD SARS-CoV-2 (2019-nCoV) Spike RBD-untagged Protein
[ Expressed in HEK293 cell, bind with ACE2 ]
   
S2 SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Protein
[ Expressed in Insect cell ]		 S2 SARS-CoV-2 (2019-nCoV) Spike S2-Fc Protein
[ Expressed in HEK293 cell ]
   
S2 SARS-CoV-2 (2019-nCoV) Spike S2-mFc Protein
[ Expressed in Insect cell ]		 ME SARS-CoV-2 (2019-nCoV) Methyltransferase-His Protein
[ Expressed in E.coli cell ]
   
Plpro SARS-CoV-2 (2019-nCoV) Plpro-His protein
[ Expressed in E.coli cell, enzymatic activity ]		 NSP9 SARS-CoV-2 (2019-nCoV) NSP9-His Protein
[ Expressed in E.coli cell ]

The S and N detection kits employ a standard sandwich ELISA, allowing rapid quantification of the N and S antigens.
• All antibodies used in the kits are in-house developed monoclonal antibodies, ensuring batch-to-batch consistency.
• These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus, as well as antigens expressed recombinantly.
SARS-CoV-2 N Detection Kit
(KIT40588)
More about SARS-CoV-2 Antigen Detection Assay

Sino Biological announced this week that the company has launched the world first coronavirus antigen array under its new brand SinommuneTM. This product is co-developed by Nanommune Inc., a UCI-based biotech company specializing in array technology. This antigen array is specifically designed for high throughput sero-surveillance studies of COVID-19 Coronavirus, and other virus that can lead to upper respiratory infections. The SinommuneTM is constructed by printing recombinant antigens on a nitrocellulose-coated membrane. It can analyze serum antibodies against 66 antigens from 23 types of viruses known to cause respiratory tract infections, including SARS-CoV-2 and the other six coronaviruses.

HCoV-OC43 HCoV-229E SARS-CoV
HCoV-NL63 HCoV-HKU1 MERS-CoV
SARS-CoV-2 Influeza virus RSV
Metapneumovirus Parainfluenza Adenovirus
More about Coroanvirus Antigen Array
 

SARS-CoV-2 (COVID-19 Virus) Research

SARS-CoV-2 (2019-nCoV, Novel Coronavirus 2019) has led to pneumonia (COVID-19) that sickened over 5.7M people worldwide. Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein.

The spike protein (S-protein) is the common target for neutralizing antibodies and vaccines. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor. S2 subunit contains other basic elements needed for the membrane fusion. SARS-CoV-2 (2019-nCoV) (ref.) can infect the human respiratory epithelial cells through interaction with huamn ACE2. Indeed, the recombinant Spike protein can bind with recombinant ACE2 protein.

The Nucleocapsid Protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.

Sino Biological is the first company in the world to produce recombinant proteins of SARS-CoV-2. We launched the spike protein on Jan 22nd, only 12 days after the sequence is published. Till this day, Sino Biological has developed a large panel of reagents for COVID19 research. The available products include hundreds of antigens (the N protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, Plpro, MTase), monoclonal antibodies, ELISA kits, and expression vectors for SARS-CoV-2 and its receptor. These reagents have supported hundreds of research groups around the globe for their vaccine and antibody development works. Sino Biological is also offering pseudovirus-based infection assay services, allowing rapid screening of antibodies and compounds for neutralization potential.

Full List of SARS-CoV-2 Reagents
 

Capacity of Viral Reagents Development

• 2009.5 Launched Recombinant Influenza A H5N1 Hemagglutinin Protein

• 2009.12 Launched Influenza A H5N1 HA ELISA Pair Set and H1N1 HA ELISA Pair Set

• 2012.12 Launched MERS-CoV Spike Protein(S1,S2,S-RBD),NP protein within 50 Days after Sequence Published.

• 2013.4 Completed R&D of H7N9 HA Protein & H7N9 NA Protein in 12 Days.

• 2013.10 Launched SARS CoV Spike Protein, NP Protein.

• 2014.2 Completed R&D of EBOV NP, GP, VP40, VP24 Proteins.

• 2016.6 Completed R&D of ZIKV Envelope, Membrane protein in 14 Days.

• 2020.1 Completed R&D of SARS-CoV-2 (2019-nCoV) Viral Proteins (Spike, S1, S2, RBD protein) in 12 Days.

View Related Viral Products

MERS-CoV

SARS-CoV

HCoV-HKU1

HCoV-NL63

HCoV-229E

HCoV-OC43

DcCoV

Influenza

H1N1

H5N1

H7N9

EBOV Virus

Zika Virus

RSV

 

Reference

• Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.SCIENCE CHINA Life Sciences.2020
• Bo Diao, Zeqing Feng.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv preprint

SARS-CoV-2 Serological Analysis

More CoV Research Reagents

Human Coronavirus Reagents
All Virus Research Reagents

Browse by Coronavirus Antigens

Coronavirus Infection Related

Coronavirus Related Information